King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
08:05
Sah: Felix Ilinca becomes a grandmaster international at just 16 years old
07:52
PSD, PNL, USR and UDMR leaders, in discussions with President Nicușor Dan on the topic of the Salary Law / Romania loses 770 million euros if it does not adopt the law
07:42
Kosovo withdraws the symbols of support for Ukraine after Zelensky's refusal to recognize its independence
07:26
The earthquake toll in Colombia has risen to at least 132 dead and 570 injured.
07:09
Chronicle - Superliga | The red-blues are paler than a newly promoted team
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
